Monopar Therapeutics Files 8-K for Regulation FD Disclosure

Ticker: MNPR · Form: 8-K · Filed: 2024-02-22T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, disclosure

TL;DR

**Monopar Therapeutics just filed an 8-K for Regulation FD disclosure, keeping investors in the loop.**

AI Summary

Monopar Therapeutics Inc. filed an 8-K on February 22, 2024, indicating a Regulation FD Disclosure and Financial Statements and Exhibits. The filing, under SEC File Number 001-39070, reports no changes to its principal executive offices at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and maintains its Delaware incorporation. This 8-K primarily serves to disclose information under Regulation FD, ensuring fair disclosure of material nonpublic information.

Why It Matters

This filing ensures Monopar Therapeutics is transparent about any material nonpublic information, maintaining compliance with SEC regulations and informing investors.

Risk Assessment

Risk Level: low — The filing is a routine disclosure under Regulation FD and does not indicate any immediate financial or operational risks.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Monopar Therapeutics Inc.?

The purpose of this 8-K filing is for Regulation FD Disclosure and to include Financial Statements and Exhibits, as reported on February 22, 2024.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on February 22, 2024.

What is Monopar Therapeutics Inc.'s Commission File Number?

Monopar Therapeutics Inc.'s Commission File Number is 001-39070.

Where are Monopar Therapeutics Inc.'s principal executive offices located?

Monopar Therapeutics Inc.'s principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

What is the state of incorporation for Monopar Therapeutics Inc.?

Monopar Therapeutics Inc. is incorporated in Delaware.

From the Filing

0001437749-24-005127.txt : 20240222 0001437749-24-005127.hdr.sgml : 20240222 20240222070022 ACCESSION NUMBER: 0001437749-24-005127 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240222 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 24662240 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240221_8k.htm FORM 8-K mnpr20240221_8k.htm false 0001645469 0001645469 2024-02-22 2024-02-22     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 22, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350, Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On February 22, 2024, Monopar Therapeutics Inc. issued a press release announcing promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program targeting advanced cancers.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release Dated February 22, 2024 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)      

View on Read The Filing